- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04027244
Leg Ischaemia Management Collaboration (LIMb)
Single-centre prospective cohort study of patients presenting with severe limb ischaemia (SLI). The primary outcome measure will be 12 month major amputation rate. A historical cohort of patients identified retrospectively will be the comparitor group used to assess the impact of a newly-established rapid-access limb salvage clinic.
Primary aim:
- Determine the proportion of patients with SLI undergoing major lower limb amputation within 12 months of presentation.
Secondary aims:
- Assess clinically important short-, medium- and long-term outcomes in those undergoing and not undergoing amputation
- Prevalence and degree of frailty and cognitive impairment
- Pevalence and degree of cardiac disease (detected by stress MRI)
- Establish a biobank for future biomarker analysis
- Investigate the role of frailty and cognitive assessments, cardiac MRI and biomarkers in risk-stratification of patients with SLI
Przegląd badań
Status
Szczegółowy opis
Severe limb ischaemia (SLI) is the end-stage of peripheral arterial occlusive disease (PAOD) whereby the viability of the limb is threatened due to the degree of arterial disease and subsequent ischaemia in the peripheral tissues. It is defined as ischaemic rest pain (or night pain) and/or ulceration or gangrene in the affected limb(s) for a minimum of two weeks attributed to confirmed PAOD. Treatment includes open surgical and endovascular revascularisation, with or without surgical debridement of affected tissues, amputation of toes and drainage of sepsis. In some patients revascularisation is not possible or fails resulting in the person requiring a major lower limb amputation.
Over 4000 major lower limb amputations per year were undertaken in England alone between 2003 and 2013 and a diabetes-related major lower limb amputation is performed every 30 seconds world-wide. As many as 25% of people with SLI will undergo a major lower limb amputation in the first year after presentation. Amputation negatively affects quality of life due to its negative impact on mobility, independence and ability to carry out activities of daily living.
This single-centre prospective cohort study will investigate the amputation rate at one year in patients presenting with SLI and compare this to a retrospectively identified historical cohort. This study will also investigate the prevelance and degree of frailty, cognitive impairment, and cardiac disease (detected by cardiac magnetic resonance imaging (MRI)), as well as establish a biobank for future biomarker analyses. The role of frailty and cognitive assessments, cardiac MRI and biomarker analysis in risk-stratifying patients with SLI will also be investigated.
Typ studiów
Zapisy (Oczekiwany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Rob D Sayers, MD
- Numer telefonu: +44 (0)116 252 3141
- E-mail: rs152@le.ac.uk
Kopia zapasowa kontaktu do badania
- Nazwa: Tanya J Payne, BSc
- Numer telefonu: +44 (0)116 258 3867
- E-mail: tjp28@le.ac.uk
Lokalizacje studiów
-
-
Leicestershire
-
Leicester, Leicestershire, Zjednoczone Królestwo, LE3 9QP
- Rekrutacyjny
- Glenfield Hospital Leicester
-
Pod-śledczy:
- Gerry P McCann, MD
-
Kontakt:
- Tanya J Payne
- Numer telefonu: +44 (0)116 358 3867
- E-mail: tjp28@le.ac.uk
-
Główny śledczy:
- Rob D Sayers, MD
-
Pod-śledczy:
- Matt J Bown, MD
-
Pod-śledczy:
- Thompson G Robinson, MD
-
Pod-śledczy:
- Victoria J Haunton, MD
-
Pod-śledczy:
- Sally J Singh, PhD
-
Główny śledczy:
- Robert SM Davies, MD
-
Pod-śledczy:
- Tanya J Payne, BSc
-
Pod-śledczy:
- Laura J Gray, PhD
-
Pod-śledczy:
- Harjeet S Rayt, MD
-
Pod-śledczy:
- Gregory S McMahon, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
PRIMARY COHORT
Inclusion Criteria:
- All patients presenting to the Leicester Vascular Institute with SLI
Exclusion Criteria:
- SLI not caused by PAOD
- Patients undergoing intervention during their index presentation prior to recruitment
- Patients lacking capacity to consent with no accompanying next of kin, relative, partner or friend who can act as a personal consulted
- Patients who cannot read, write or understand English
- Any significant disease or disorder which may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study
FRAILTY & COGNITIVE ADDITIONAL ASSESSMENTS
Inclusion criteria:
- Patients recruited to the primary cohort in whom a decision has been made to undergo an intervention for SLI
- Patients aged ≥65 years
Exclusion criteria:
- Nil additional
CARDIAC MRI ADDITIONAL ASSESSMENTS
Inclusion criteria:
- Patients recruited to the primary cohort in whom a decision has been made to undergo an intervention
Exclusion criteria:
- Absolute contraindications to cardiac MRI (Pregnancy, Non-MR safe permanent pacemaker, implanted cardiac defibrillator, intra-auricular implant or intra-cranial clips, severe claustrophobia, unstable angina)
- Contraindication to gadolinium contrast agent (Known adverse reaction, chronic renal failure (eGFR <30mL/min/1.73m^2))
- Patients lacking capacity to consent for cardiac MRI
BIOMARKERS ADDITIONAL ASSESSMENTS
- Patients recruited to the primary cohort in whom a decision has been made to undergo an intervention
Exclusion criteria:
- Nil additional
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
---|
Primary cohort
Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).
|
Frailty & cognitive additional assessments
Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).
|
Cardiac MRI additional assessments
Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).
|
Biomarkers additional assessments
Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).
|
Historical cohort
Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
12 month amputation rate
Ramy czasowe: 12 months post recruitment
|
Proportion of patients undergoing major lower limb amputation
|
12 months post recruitment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Amputation free survival
Ramy czasowe: ≥12 months post recruitment
|
Composite outcome measure of death or amputation
|
≥12 months post recruitment
|
All-cause mortality
Ramy czasowe: ≥12 months
|
Death from any cause
|
≥12 months
|
Quality of life
Ramy czasowe: 12 and 24 months post recruitment
|
Quality of life as measured by the Vascular Quality of Life questionnaire (VascuQoL)
|
12 and 24 months post recruitment
|
Disability
Ramy czasowe: 12 and 24 months post recruitment
|
Level of disability as measured by the Barthel Index - Score 0-20; higher score = greater degree of functional independence/lower level of disability |
12 and 24 months post recruitment
|
Clinical Frailty Scale
Ramy czasowe: Baseline, 12 and 24 months
|
Prevalence and degree of frailty as measured by the Clinical Frailty Scale (CFS)
|
Baseline, 12 and 24 months
|
Anxiety & Depression
Ramy czasowe: Baseline, 12 and 24 months
|
Prevalence and degree of anxiety and depression as measured by the Hospital Anxiety and Depression Scale (HADS)
|
Baseline, 12 and 24 months
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Cognitive impairment (Frailty & Cognitive additional assessments only)
Ramy czasowe: Baseline, 3 and 12 months
|
Prevalence of cognitive impairment as detected by the Montreal Cognitive Assessment (MoCA)
|
Baseline, 3 and 12 months
|
Post-operative delirium (Frailty & Cognitive additional assessments only)
Ramy czasowe: 24 and 72 hours post intervention
|
Incidence of post-operative delirium as detected by the Single Question in Delirium (SQiD) +/- 4 A's Test for delirium (4AT)
|
24 and 72 hours post intervention
|
Prevalence of coronary artery disease (Cardiac MR additional assessments only)
Ramy czasowe: Baseline
|
Prevalence of coronary artery disease as detected by stress cardiac MRI
|
Baseline
|
Incidence of peri-operative myocardial infarction (Cardiac MR additional assessments only)
Ramy czasowe: 2-4 months post intervention
|
Incidence of peri-operative myocardial infarction as detected by cardiac MRI
|
2-4 months post intervention
|
Edmonton Frail Scale (Frailty & Cognitive additional assessments only)
Ramy czasowe: Baseline, 3 and 12 months
|
Prevalence and degree of frailty as measured by the Edmonton Frail Scale (EFS)
|
Baseline, 3 and 12 months
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Krzesło do nauki: Rob D Sayers, MD, University of Leicester
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 0686
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Choroba wieńcowa
-
Bambino Gesù Hospital and Research InstituteZakończonyCiężka otyłość dziecięca (BMI > 97° szt. -według wykresów BMI Centers for Disease Control and Prevention-) | Zmienione testy czynnościowe wątroby | Nietolerancja glikemicznaWłochy
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
-
Janssen Pharmaceutical K.K.RekrutacyjnyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Republika Korei, Japonia
-
Adelphi Values LLCBlueprint Medicines CorporationZakończonyBiałaczka z komórek tucznych (MCL) | Agresywna mastocytoza układowa (ASM) | SM w Assoc Clonal Hema Lineage Non-mast Cell Lineage Disease (SM-AHNMD) | Tląca się mastocytoza układowa (SSM) | Indolentna układowa mastocytoza (ISM) Podgrupa ISM w pełni zatrudnionaStany Zjednoczone